Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Current insights and progress in the clinical management of head and neck cancer
Simple Summary Head and neck cancer (HNC) incidence has been steadily increasing
since the 1990s. While the multimodal treatment approach for localized HNC is well …
since the 1990s. While the multimodal treatment approach for localized HNC is well …
[HTML][HTML] Immunotherapy for the treatment of squamous cell carcinoma: potential benefits and challenges
TM Ansary, MDR Hossain, M Komine… - International Journal of …, 2022 - mdpi.com
Melanoma and nonmelanoma skin cancers (NMSCs) are recognized as among the most
common neoplasms, mostly in white people, with an increasing incidence rate. Among the …
common neoplasms, mostly in white people, with an increasing incidence rate. Among the …
Map** the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment
Head and neck squamous cell carcinomas (HNSCCs) are the seventh most common cancer
and represent a global health burden. Immune checkpoint inhibitors (ICIs) have shown …
and represent a global health burden. Immune checkpoint inhibitors (ICIs) have shown …
Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives
S Pannunzio, A Di Bello, D Occhipinti, A Scala… - Frontiers in …, 2024 - frontiersin.org
Squamous cell carcinoma of the head and neck is a complex group of diseases that
presents a challenge to the clinician. The prognosis in the recurrent/metastatic disease is …
presents a challenge to the clinician. The prognosis in the recurrent/metastatic disease is …
Stereotactic body radiotherapy for extracranial oligometastatic disease from head and neck primary cancers: a systematic review and meta-analysis
Simple Summary Question: Is stereotactic body radiation therapy an effective and safe
treatment option for patients with oligometastatic cancer from a head and neck primary …
treatment option for patients with oligometastatic cancer from a head and neck primary …
[HTML][HTML] Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase Ⅱ study
Y Shi, L Gao, Y Tian, C Bai, J Chen, J Wang, X Li… - ESMO open, 2023 - Elsevier
Background Treatment regimens for recurrent or metastatic head and neck squamous cell
carcinoma (R/M HNSCC) after failure of platinum-based chemotherapy have been illustrated …
carcinoma (R/M HNSCC) after failure of platinum-based chemotherapy have been illustrated …
Mechanisms of resistance and therapeutic perspectives in immunotherapy for advanced head and neck cancers
A Meci, N Goyal, G Slonimsky - Cancers, 2024 - mdpi.com
Simple Summary The programmed death-1 receptor monoclonal antibody treatments
pembrolizumab and nivolumab have been successful in the treatment of recurrent or …
pembrolizumab and nivolumab have been successful in the treatment of recurrent or …
[HTML][HTML] Gold nanoparticles enhance the tumor growth-suppressing effects of cetuximab and radiotherapy in head and neck cancer in vitro and in vivo
T Sato, Y Kakei, T Hasegawa, M Kashin, S Teraoka… - Cancers, 2023 - mdpi.com
Simple Summary Head and neck squamous cell carcinoma (HNSCC) treatment includes
surgery, radiotherapy, and immunotherapy with the aim of eradicating cancer cells without …
surgery, radiotherapy, and immunotherapy with the aim of eradicating cancer cells without …
[HTML][HTML] Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their …
S Georgopoulou, J Droney, PP Jaganathan… - Cancer Treatment …, 2024 - Elsevier
Background The implementation of patient-reported outcome measures (PROMs) in the
clinical identification of immunotherapy toxicities is a complex intervention. There has been …
clinical identification of immunotherapy toxicities is a complex intervention. There has been …
Association of neoadjuvant pembrolizumab for oral cavity squamous cell carcinoma with adverse events after surgery in treatment-naive patients
Importance Pembrolizumab, a monoclonal antibody targeting programmed cell death 1, is
currently approved by the US Food and Drug Administration for recurrent or metastatic head …
currently approved by the US Food and Drug Administration for recurrent or metastatic head …